加替沙星在正常与肝损害模型家犬体内的药动学比较研究

目的:比较加替沙星在正常与肝损害模型家犬体内的药动学。方法:家犬腹腔注射四氯化碳溶液,建立肝损害模型;给药 后分别在规定时间点取样,以高效液相色谱法测定各时间点加替沙星血药浓度,利用3p87软件计算其药动学参数,并与正常家犬 比较。结果:加替沙星在正常家犬与肝损害模型家犬体内分布均呈一室模型,tmax分别为(2．35±0．75)h、(1．06±0．32)h,t1／2ke分 别为(8．38±2．03)h、(8．91±1．21)h,Cmax分别为(2．29±0．11)、(2．63±0．07)mg／L,AUC分别为(33．82±6．78)、(36．80± 4．67)(μg·h)／ml,经t检验无显著性差异(P>0．05)。结论:加替沙星在正常与肝损害模型家犬体内药动学比较无显著性影响。

Comparative Study on in Vivo Pharmacokinetics of Gatifloxacin between Normal Canis Familiaris and Hepatic Injury Model

OBJECTIVE: To compare the in vivo pharmacokinetics of gatifloxacin between normal canis familiaris and hepatic injury model group. METHODS: Hepatic injury model was established by injecting canis familiaris intraperitoneally with carbon tetrachloride solution. Samples were taken respectively following the specified time schedule after administration with gatifloxacin. Blood concentrations of which at different time were determined by HPLC. The pharmacokinetic parameters were calculated with 3p87 program software and the results were compared with those of the normal group. RESULTS: The main pharmacokinetic parameters of gatifloxacin in the normal group and the hepatic injury model group all assumed one compartment model. The main pharmacokinetic parameters of gatifloxacin of the normal group and the model groups were respectively as follows: tmax were (2.35±0.75) h and(1.06±0.32) h, t1/2ke were (8.38±2.03) h (8.91±1.21) h, Cmax were (2.29±0.11)mg/L and (2.63±0.07)mg/L; AUC were (33.82±6.78)(μg·h)/ml and (36.80±4.67)(μg·h)/ml. No significant difference was noted between the two groups from the t - test(P > 0.05) . CONCLUSION: Gatifloxacin has no significant influence on pharmacokinetics of the hepatic injury model group as compared with the normal group.